Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 2/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30954744 | 1.00 | TNKS (0.46) | TNKSTNKS2MEN1CYP2C9KMT2A | |
| SCHEMBL21029007 | 0.85 | TNKS (0.43) | TNKSTNKS2IDO1AVPR1ASCD | |
| SCHEMBL30079574 | 0.85 | TNKS (0.43) | TNKSTNKS2IDO1AVPR1ASCD | |
| SCHEMBL8353525 | 0.81 | TNKS (0.46) | TNKSTNKS2MEN1CYP2C9KMT2A | |
| SCHEMBL15144578 | 0.79 | TNKS (0.43) | TNKSTNKS2IDO1AVPR1ASCD | |
| SCHEMBL8354016 | 0.79 | TNKS (0.47) | TNKSTNKS2IDO1AVPR1ASCD | |
| SCHEMBL8402825 | 0.77 | CA9 (0.38) | TNKSTNKS2MEN1KMT2A | |
| SCHEMBL30954739 | 0.76 | TNKS (0.39) | TNKSTNKS2IDO1AVPR1ASCD | |
| SCHEMBL238700 | 0.76 | TNKS (0.41) | TNKSTNKS2MEN1CYP2C9KMT2A | |
| SCHEMBL655103 | 0.76 | TNKS (0.41) | TNKSTNKS2IDO1AVPR1AOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024125488-A1 | AROMATIC AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 浙江海正药业股份有限公司 | 2024-06-20 | — | — | WO | disclosed |
| US-11203592-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203592-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-21 | — | — | US | disclosed |
| US-20210221806-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-07-22 | — | — | US | disclosed |
| US-20210221806-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | BRISTOL-MYERS SQUIBB COMPANY | 2021-07-22 | — | — | US | disclosed |
| US-5972979-A | Tricyclic spiro compounds as 5HT1D receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-10-26 | — | — | US | disclosed |
| US-5952325-A | Tricyclic spiro compounds process for their preparation and their use of 5HT1D receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1999-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11203592-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | TNKS 775/4885TNKS2 766/4885MEN1 1036/4885 |
| US-20210221806-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF THEIR USE | IDO1, IDO2, INMT | TNKS 775/4885TNKS2 766/4885MEN1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.